Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064810 | 0.94 | CNR2 (0.86) | CNR2UTS2RCNR1HDAC1HDAC8 | |
| SCHEMBL15064483 | 0.87 | CNR2 (0.76) | CNR2UTS2RCNR1HDAC1HDAC8 | |
| SCHEMBL15064502 | 0.87 | CNR2 (1.00) | CNR2UTS2RCNR1 | |
| SCHEMBL15064721 | 0.85 | CNR2 (0.72) | CNR2HTTUTS2RALDH1A1CNR1 | |
| SCHEMBL15064779 | 0.82 | CNR2 (1.00) | CNR2HTTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL5753769 | 0.78 | CNR2 (0.61) | CNR2HTTUTS2RKDM4EALDH1A1 | |
| SCHEMBL15064531 | 0.78 | CNR2 (0.74) | CNR2UTS2RHDAC1HDAC8 | |
| SCHEMBL8802827 | 0.74 | HTT (1.00) | CNR2HTTTDP1KDM4EALDH1A1 | |
| SCHEMBL15012212 | 0.73 | CNR2 (0.66) | CNR2UTS2RKDM4EALDH1A1CYP3A4 | |
| SCHEMBL714137 | 0.73 | HDAC1 (0.63) | CNR2KDM4EALDH1A1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-05 | — | — | US | disclosed |
| US-9376380-B2 | Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140296294-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIV PITTSBURGH (US) | 2014-10-02 | — | — | US | disclosed |
| US-8772541-B2 | Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296294-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885HTT 3836/4885UTS2R 449/4885 |
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885HTT 3883/4885UTS2R 432/4885 |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885HTT 3836/4885UTS2R 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.